LCTX EBITDA Growth
Lineage Cell Therapeutics, Inc. Common Stock · EBITDA Growth
LCTX EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-149.17%period ending
LCTX TTM EBITDA YoY % (-20.00% → -149.17%)
Year-over-year change
High-resolution chart · PNG
LCTX ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -149.1739% | |
| -177.1276% | |
| -136.5993% | |
| -113.3673% | |
| 37.5101% | |
| 32.1228% | |
| 20.4382% | |
| 19.9134% | |
| -3.9532% | |
| 5.2425% | |
| 9.9462% | |
| 48.1098% | |
| 54.701% | |
| 49.7227% | |
| 47.733% | |
| -81.6111% | |
| -114.0337% | |
| -96.9604% | |
| -96.6323% | |
| -2.888% | |
| 11.499% | |
| 20.1098% | |
| 31.9657% | |
| 36.2391% | |
| 35.8029% | |
| 22.1708% | |
| 5.1652% | |
| -5.793% | |
| -13.561% | |
| -5.0027% | |
| -1.258% | |
| 5.1735% | |
| 7.3568% | |
| 12.1972% | |
| 31.0854% | |
| 38.806% | |
| 44.7682% | |
| 38.6972% | |
| 8.8384% | |
| -18.7413% | |
| -45.0554% | |
| -44.1428% | |
| -29.7176% | |
| -29.0837% | |
| -20.2104% | |
| -32.3199% | |
| -32.5724% | |
| -36.0683% | |
| -53.4348% | |
| -48.8597% | |
| -56.0047% | |
| -46.7066% | |
| -37.8122% | |
| -35.2085% | |
| -34.3646% | |
| -41.7384% | |
| -42.6812% | |
| -60.6561% | |
| -84.8317% | |
| -270.8717% | |
| -188.2491% | |
| -213.5167% | |
| -180.252% | |
| 32.5573% | |
| -20.3398% | |
| 1.3201% | |
| -2.7657% | |
| -145.6505% | |
| -137.5483% | |
| -247.5343% | |
| -158.2124% | |
| 21.96% | |
| 47.9665% | |
| 69.8725% | |
| 65.0438% | |
| -73.9296% | |
| -60.342% | |
| -99.0618% | |
| -70.6467% | |
| 17.6687% | |
| 9.0191% | |
| 19.0703% | |
| -118.7095% | |
| -373.3925% | |
| -1,046.4469% | |
| -4,267.8422% | |
| -4.6308% | |
| 62.7165% | |
| 82.3751% | |
| 96.316% | |
| 39.6339% | |
| -2.5398% | |
| 49.5976% | |
| 49.1378% | |
| 53.8357% | |
| 70.2583% | |
| 51.3111% | |
| 42.3298% | |
| 36.9199% | |
| 26.7574% |